Start Here

Pillars

Practice — how to do it Science — research The Root — origin, lineage & manifesto Member Stories — first-person The Mycelium — news & pop culture Voices — podcasts & creators
FAQ Dictionary Browse Everything
Connect Contact

The Science

What Is Microdosing? The Honest Primer

What microdosing actually is, how it works, who it's for, what it isn't, and what the research does and doesn't support. The plain-language primer the rest of the internet should have written.

By The Microdose Movement ·

Microdosing is the practice of taking a very small, sub-perceptual amount of a psychedelic substance (most commonly psilocybin, from psilocybin-containing mushrooms) on a structured schedule, for the purpose of subtle, day-to-day changes in mood, cognition, creativity, or emotional regulation, rather than for a psychedelic experience.

That’s the honest one-sentence definition. Everything else on this page is the long version. Most of what gets written about microdosing is either hype, fear, or a sales pitch. We’re not going to do any of those. We’re going to tell you what it is, what it isn’t, what the research actually supports, what it doesn’t support, what it feels like, and what the honest questions are before you decide whether to try it.

The short version

A microdose of psilocybin is about one-tenth to one-twentieth of a full psychedelic dose. For dried Psilocybe cubensis mushrooms, that works out to roughly 0.1 to 0.3 grams, compared to a “macro” dose of 2 to 5 grams. At the microdose level, you do not hallucinate. You do not see the walls breathe. You do not dissolve into the carpet. You do the dishes, write your email, go to work, pick the kids up from school. What you may notice is a small softening of the edges: less reactivity, a little more mental flexibility, a slightly warmer mood. And then, at the end of the day, you remember that you took something, and you notice that the day was slightly different.

The whole thing is built on two premises. One, that the same molecule that produces dramatic effects at a high dose may produce subtle-but-real effects at a fraction of that dose. Two, that those subtle effects, repeated on a structured schedule over weeks, may compound into something worth noticing: in mood, in cognition, in creative flow, in emotional regulation.

Whether those two premises are true is the central question of the entire practice, and the honest answer is: the anecdotal evidence is strong, the peer-reviewed evidence is mixed, the mechanism is partially understood, and it is still early. If anyone tells you it is settled either way, they are wrong.

How microdosing actually works (in the body)

When you swallow a microdose of psilocybin-containing mushrooms, the psilocybin is rapidly dephosphorylated in your gut and small intestine (and to a lesser extent in the kidneys and blood) into psilocin, the actual psychoactive molecule. This happens so quickly and completely that virtually no psilocybin itself ever shows up in a blood test after oral ingestion. By the time it gets into circulation, it’s psilocin. Psilocin’s chemical structure is very close to serotonin, one of your brain’s primary mood-regulating neurotransmitters, and it binds to a specific serotonin receptor called 5-HT2A. That receptor is found in high concentrations in the prefrontal cortex, the part of the brain involved in planning, perspective-taking, self-awareness, and regulating emotional reactivity.

At a full psychedelic dose, activating 5-HT2A throughout the brain produces the cascade of perceptual and cognitive changes most people call a “trip.” At a microdose, the activation is much more limited. You are nudging the system, not flooding it. What psilocin appears to do in that nudge is two things:

One, it appears to promote neuroplasticity, the growth of new connections between neurons. Animal studies from the last five years have shown that psilocin can measurably increase the density of dendritic spines (the tiny branching structures that neurons use to form synapses) in ways that look similar to what SSRIs do, but faster and with a clearer mechanism. This is one of the more robust findings in the modern research and it is the biochemical basis for the claim that microdosing “rewires” the brain.

Two, it appears to temporarily quiet something called the Default Mode Network, a set of brain regions active when you are not doing anything in particular. It is the voice in your head that narrates your day, rehearses old arguments, worries about tomorrow, replays what you said at that party three years ago. Quieting the Default Mode Network, even a little, tends to produce what people describe as a sense of “stepping out of the loop.” More presence. More space between a stimulus and your reaction. Less rumination. The acute studies on quieting the DMN are mostly from full-dose psilocybin research. How much of that quieting happens at a microdose is an open question, but the anecdotal reports are consistent with it.

These are the two main mechanisms, as best as we understand them. The rest is noise, speculation, and marketing.

What a microdose actually feels like

Most people do not feel much, especially in the first week. This is the most important sentence in this article and the one most beginners ignore. The default expectation, shaped by influencer content and breathless testimonials, is that a microdose should produce a noticeable, positive, immediate shift. It usually does not. What it usually produces is small: slightly better sleep, slightly less reactivity, a morning that feels a little easier to start. Possibly nothing at all on any given day.

The real effect, when it shows up, shows up in aggregate. You notice it not on the day of the dose but in the spacing between the old reaction and the new one. A week in, you catch yourself not snapping at your partner over something that would have set you off last month. Two weeks in, you notice you did not lie in bed for twenty minutes replaying the meeting. Three weeks in, you notice you have been writing again, or exercising, or making the call you had been putting off. The practice works by removing a layer of internal static, not by adding a layer of perceptible effect.

People who approach the practice looking for a high will almost always conclude that microdosing “doesn’t work” because they are looking for the wrong thing. People who approach it looking for a softening of the daily pattern are much more likely to find it.

There are also people for whom it genuinely does not work. Nothing shifts. No softening. No creative return. The honest picture includes that group. Microdosing is not a universal protocol. It is not a panacea. The responder/non-responder split in the anecdotal data is real, and the emerging scientific literature is starting to characterize who tends to respond and who does not. That is unresolved, and we will tell you so as clearly as we can.

The protocols: how people actually do it

Microdosing is not a one-size-fits-all schedule. There are several well-known protocols, each with a different rhythm and a different purpose. The best-studied and most popular is:

The Fadiman Protocol

Developed by the psychologist James Fadiman, this is the schedule most Western microdosers start with. It’s simple:

Fadiman’s reasoning for the two off days is that tolerance to psilocin builds fast (within hours) and takes about 72 hours to fully clear. Dosing every three days gives the receptors time to reset so each dose hits a fresh system. The off days are also where integration happens, where you actually notice what shifted. The two-week break at the end of a cycle is mandatory and the mistake most beginners make is skipping it.

Read more about the Fadiman Protocol and what the research shows →

The Stamets Stack

Developed by the mycologist Paul Stamets, this protocol adds two supplements to the psilocybin microdose: Lion’s Mane mushroom (for nerve growth factor) and niacin (to help psilocybin cross the blood-brain barrier more efficiently). The schedule is different too:

The theory behind the Stamets Stack is that the three compounds act on overlapping aspects of neurogenesis and neuroplasticity, producing greater cognitive benefit than psilocybin alone. The theory is plausible and the anecdotal data is enthusiastic. The actual research specifically on the combined stack is thin; the Quiet Mind Foundation’s volunteer study collected self-reports but has not been published in a peer-reviewed journal. Treat the Stamets Stack as a reasonable experiment, not a proven protocol.

Read the full Farming Node guide, which covers the Stamets Stack protocol in detail →

Intuitive and custom rhythms

Experienced practitioners often develop their own rhythms, microdosing when they feel they need it, pausing when they don’t, adjusting dose size based on the work they are doing that week. This is harder to recommend because it requires a calibrated sense of what the medicine does for you specifically, which you can only develop after following a structured protocol for long enough to have a baseline. Intuitive microdosing is not for beginners.

What microdosing is for (and who it tends to help)

The honest answer is that different people come to the practice for different reasons, and the research is catching up to that. Here are the most common use cases, paired with what the research actually supports.

Depression and anxiety. The adjacent high-dose psilocybin research at Imperial College London, Johns Hopkins, and Compass Pathways has shown meaningful antidepressant effects from structured psilocybin-assisted therapy sessions. Whether microdoses produce similar effects is much less clear. The self-report data is strong and trending positive. The controlled trials are mixed, with some studies finding substantial effects and others finding results indistinguishable from placebo. The longer write-up here.

ADHD and focus. A smaller research cluster looking at psilocybin for attention-related challenges. Some people report significant improvement in focus and executive function; others report the opposite (anxiety, scattering). The stimulant-adjacent crowd is the most active experimental community here. More on microdosing and ADHD.

Creative work and cognitive flexibility. The oldest anecdotal use case: creative professionals reporting easier access to new ideas and looser cognitive constraints. The research is thin but growing. The self-reports are consistent.

Emotional regulation and relationships. People using microdosing specifically to be more present with their families, less reactive in conversations, better able to hold space. This is one of the most common actual use cases and one the mainstream research conversation almost never names. Anecdotal reports are very positive; controlled research is nearly nonexistent.

Trauma integration. Microdosing as an adjunct to somatic trauma therapy or integration work. Not a replacement for therapy, but a tool that appears to loosen resistance just enough to make the therapy go further. This is the highest-risk use case and the one where we most strongly recommend working with a qualified clinician. More in the Foraging Shadow guide.

Not for peak experience. This is worth naming specifically because it’s the one place the practice gets abused. A microdose is not a party drug. It is not for “a little boost” at a concert. It is not for taking before a social event because you’re nervous. Those uses are not dangerous but they are the opposite of what the practice is actually for, and treating microdosing as a recreational modifier will produce no meaningful results and plenty of disappointed readers of our site.

What microdosing is NOT

This is the part most articles skip. Here is the honest list of things microdosing is not.

Microdosing is not a shortcut. The microdose creates a window of slightly increased openness, flexibility, and pattern-noticing. What you do with that window is the work. If you take a microdose and then sit in front of your phone for three hours, nothing meaningful happens. The practice is microdosing plus integration: journaling, noticing, adjusting, paying attention. Without the integration, it’s just a slightly altered Tuesday.

Microdosing is not a replacement for therapy. For people working through trauma, mental health challenges, or long-standing patterns, the medicine alone does not do the healing. It appears to assist the healing by making the therapy more effective. If you are using microdosing to avoid therapy, you are using it wrong.

Microdosing is not safe for everyone. The honest safety picture:

Microdosing is not legal in most places. Psilocybin remains a Schedule I substance in the United States and most countries, which means possession, sale, and use are federally illegal regardless of local decriminalization. A handful of jurisdictions (Oregon, Colorado, some municipalities) have decriminalized personal use or authorized regulated therapy programs. We keep a current state-by-state tracker here. The legal question is yours to answer for yourself; we provide the information, not the decision.

Microdosing is not a product. It is a practice. The Microdose Movement does not sell anything. We don’t have gummies, capsules, tinctures, or chocolate bars to sell you. If someone’s “information about microdosing” is really a funnel to their store, run it through a skeptical filter.

Common questions, honest answers

Will I feel anything?

Probably not on day one. Possibly not in the first week. The effect is cumulative. If you feel a dramatic shift in the first 48 hours, you either took too much or you are riding a placebo-expectation wave. Adjust expectations down, not up.

Can I microdose while working?

That is the point, for most protocols. The Fadiman protocol in particular is designed for people who have jobs, families, and responsibilities. You should not be impaired at a proper microdose. If you are (if your coordination is off, your speech is slurred, your thinking is cloudy) you have overdosed your microdose, which is to say: your next dose should be lower.

How do I know if it’s working?

Write it down. The single most important piece of advice in this whole article. Keep a journal, even a short one. Rate your mood, energy, reactivity, sleep, and focus each day. After three or four weeks you will have enough data to see what the pattern actually looks like, rather than trusting your memory of “how I felt this week.” People who skip the journal consistently mistake their progress for nothing.

How long before I know?

Most people who are going to notice something notice it within 3 to 6 weeks of consistent practice. If you have followed a structured protocol for 8 weeks and honestly noticed nothing, microdosing may not be for you, or the dose may be wrong for you, or the substance may be wrong for you. It is a real possibility and we would rather tell you that than pretend it works for everyone.

Is it addictive?

No. Psilocybin does not activate the dopamine reward system in the way addictive substances do, and there is no withdrawal syndrome. Tolerance builds fast and clears in about 72 hours, which is why the protocols have off days. Compulsive use of psilocybin is rare in the literature and the clinical profile is very different from the profile of addiction. More in the safety primer.

Can I overdose?

Not in the toxicological sense. Psilocybin has one of the widest margins of safety of any psychoactive substance. The LD50 (lethal dose) in rodent studies is roughly a thousand times higher than the effective dose. The real risk with microdosing is not acute toxicity but unintentionally taking more than a microdose, which produces an altered state you may not be prepared for while trying to work, drive, or parent. Start low. Weigh carefully. Use a milligram scale.

What the Movement actually thinks

This is a long piece and it has been honest at the cost of being exciting. That is the trade we are willing to make. The microdosing conversation has been dominated for years by content that oversells the benefits and hides the questions, and by content from the opposite side that dismisses the whole practice as placebo without engaging with the actual research. Both of those are wrong.

The honest position, as we see it in April 2026:

If you are considering starting, the honest next step is to figure out which archetype fits your situation, read the guide written for that archetype, and decide for yourself whether the practice is for you. We built this site to give you the information that would let you make that decision without anybody selling you anything. That is what it is for.

Sources and Further Reading

The Microdose Movement is an educational community, not a medical provider. Nothing in this article is medical advice. Psilocybin is illegal in most jurisdictions. If you are in a mental health crisis, please contact your local emergency services or a crisis helpline.